Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Algorithm for immunosuppressive treatment

Published byΕυδοξία Διαμαντόπουλος Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Algorithm for immunosuppressive treatment"— Presentation transcript:

1 Figure 2 Algorithm for immunosuppressive treatment
of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides Figure 2 | Algorithm for immunosuppressive treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.Standard induction treatment is with cyclophosphamide and glucocorticoids, with alternatives for milder or more severe disease. Standard maintenance treatment is with azathioprine or methotrexate, which should be continued for longer than the glucocorticoids. Modified with permission from Nature Publishing Group © Schönermarck, U. et al. Nat. Rev. Nephrol. 10, 25–36 (2014). Collins, M. P. & Hadden, R. D. (2017) The nonsystemic vasculitic neuropathies Nat. Rev. Neurol. doi: /nrneurol

Download ppt "Figure 2 Algorithm for immunosuppressive treatment"

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.
Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi:10/1038/nrneurol
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Electromechanical properties of OIHPs

Figure 2 Electromechanical properties of OIHPs
Figure 6 Selected examples of TERS applications in material systems

Figure 6 Selected examples of TERS applications in material systems
Figure 4 Progression-free survival, according to treatment group

Figure 4 Progression-free survival, according to treatment group
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 1 Role of innate lymphoid cells (ILCs) in steady state,

Figure 1 Role of innate lymphoid cells (ILCs) in steady state,
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 4 Time course of the development of physiological changes

Figure 4 Time course of the development of physiological changes
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 2 Overview of risk factors for Parkinson disease dementia

Figure 2 Overview of risk factors for Parkinson disease dementia
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Similar presentations

Ads by Google